



A.G. Duffy¹, Chi Ma¹, S.V.Ulahannan¹, O.Rusher¹, S.Fioravanti¹, M.Walker¹, S.Carey¹, A.M. Venkatesan², B.Turkbey³, P.Choyke³, J. Trepel⁴, L.Cao, K. Bollen⁵, W.D.Figg⁵, T.F.Greten¹. ¹Gastrointestinal Malignancy Section; ²Radiology and Imaging Sciences; ³Molecular Imaging Department; ⁴Developmental Therapeutics Branch; ⁵Clinical Pharmacology Program; Center for Cancer Research; National Cancer Institute, National Institutes of Health, Bethesda, MD.

Introduction

Sorafenib is an oral multi-kinase inhibitor of vascular endothelial growth factor (VEGF) receptor, the platelet-derived growth factor (PDGF) receptor, and Raf and was the first systemic medical therapy to prolong survival in HCC based on the SHARP study which demonstrated a median overall survival benefit compared to placebo(10.7 months v 7.9 months; HR 0.69; P<0.001). Since the SHARP study, attempts to combine agents with sorafenib have been disappointing.

Endoglin (CD105) is a transmembrane receptor overexpressed by proliferating endothelial cells that is required for angiogenesis and upregulated by hypoxia in response to VEGF inhibition. TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 with high avidity and inhibits binding of its key ligand, bone morphogenic protein. TRC105 inhibits angiogenesis and mediates apoptosis and antibodydependent cell-mediated cytotoxicity (ADCC) of proliferating endothelium.

Preclinical data:





Figure 1: Detection of endoglin expression In BNL hepatocellular tumors growing subcutaneously and treated with sorafenib.

Preclincal data (1): <u>CD105 expression</u> after sorafenib treatment.

BNL tumors in Balb/c mice were treated with Sorafenib (10 mg/kg/d). Tissue was harvested after 3 days and analyzed. As shown in Figure 1, sorafenib treatment induced an increase in endoglin expression compared to control.



Clinical trial:



✓ To establish the MTD for TRC105 when given with sorafenib in HCC.

✓ Pharmacodynamic Biomarkers

✓ VEGF, PIGF, bFGF, sVEGFR1, soluble CD105 ✓DCE-MRI


✓ Preliminary Evidence of Anti-Tumor Response


✓ Response rate and PFS

A Phase 1/2 Study Of TRC105 In Combination With Sorafenib In Hepatocellular Carcinoma (HCC)

ose (mg/d)	TRC-105 dose (mg/kg)					
0	3					
0	6					
0	10					
0	15					

Characteristic HCC / FLHCC Male/Female Mean Age (Range) Cirrhosis (Yes/No) Hepatitis B/C/NA Administered cycles Mean (Range) Best Response PR SD Not evaluable/clinical progression/PD Table 1: Patient characteristics





CONCLUSIONS: phase 2 stage.

No. of pts	Toxicity Dose levels (N)					
17/1	(Grade ≥ 3)	1	2	3	4	Т
12/6		N=3	N=3	N=6	N=6	
60 (18 – 76)	Anemia			1		1
11/7	Hand-foot syndrome	1	1	1		3
	Hypophosphatemia	1		1		2
2/9/7	Intracranial hem.		1			1
	AST/ALT elevation	1		3	2	6
4.75 (2-22)	Diarrhea	1				1
	Hepatic failure		1		1	2
3	Neutropenia					1
10(N=1, 22m)	Amylase/lipase inc.			1		1
5	Cardiac ischemia			1(G5)		1
	Hypertension			1		1

TRC105 combined with sorafenib was well tolerated at the recommended single agent doses of both drugs. Encouraging evidence of activity was observed and the study is proceeding to the